Cargando…

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial

Predicting an individual's risk of treatment discontinuation is critical for the implementation of precision chemoprevention. We developed partly conditional survival models to predict discontinuation of tamoxifen or anastrozole using patient-reported outcome (PRO) data from postmenopausal wome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calsavara, Vinicius F., Henry, Norah L., Hays, Ron D., Kim, Sungjin, Luu, Michael, Diniz, Márcio A., Gresham, Gillian, Cecchini, Reena S., Yothers, Greg, Ganz, Patricia A., Rogatko, André, Tighiouart, Mourad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618646/ https://www.ncbi.nlm.nih.gov/pubmed/37756580 http://dx.doi.org/10.1158/1940-6207.CAPR-23-0216

Ejemplares similares

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
por: Henry, N. Lynn, et al.
Publicado: (2022)

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35
por: Henry, N. Lynn, et al.
Publicado: (2021)

Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index
por: Gresham, Gillian, et al.
Publicado: (2020)

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
por: Diniz, Márcio A., et al.
Publicado: (2021)

Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data
por: Calsavara, Vinicius F., et al.
Publicado: (2022)

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04
por: Ganz, Patricia A., et al.
Publicado: (2022)

On the properties of the toxicity index and its statistical efficiency
por: Razaee, Zahra S., et al.
Publicado: (2020)

Comparison between continuous and discrete doses for model based designs in cancer dose finding
por: Diniz, Márcio Augusto, et al.
Publicado: (2019)

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
por: Advani, Pooja P., et al.
Publicado: (2023)

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades
por: Diniz, Márcio A, et al.
Publicado: (2020)

Erratum to: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021)

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
por: Kim, S Rim, et al.
Publicado: (2018)

Escalation with Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials
por: Tighiouart, Mourad, et al.
Publicado: (2014)

Evaluation of three APBI techniques under NSABP B‐39 guidelines
por: Scanderbeg, Daniel, et al.
Publicado: (2009)

A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials
por: Tighiouart, Mourad, et al.
Publicado: (2016)

Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding
por: Rogatko, André, et al.
Publicado: (2015)

Primary chemotherapy for operable breast cancer: the NSABP experience
por: Bear, HD
Publicado: (2005)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

The Integrated Web Portal for Escalation with Overdose Control (EWOC)
por: Wang, Haibin, et al.
Publicado: (2013)

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020)

caGrid-Enabled caBIG(TM) Silver Level Compatible Head and Neck Cancer Tissue Database System
por: Wang, Haibin, et al.
Publicado: (2010)

MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice
por: Paterson, Alexander H G, et al.
Publicado: (2021)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial
por: Rogatko, Cleo P., et al.
Publicado: (2021)

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
por: Abraham, Jame, et al.
Publicado: (2019)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2019)

Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable: A Secondary Analysis of the RTOG 9408 Randomized Clinical Trial
por: Zumsteg, Zachary S., et al.
Publicado: (2020)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2020)

Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group
por: Ganz, Patricia A., et al.
Publicado: (2009)

Talking numbers: how women and providers use risk scores during and after risk counseling – a qualitative investigation from the NRG Oncology/NSABP DMP-1 study
por: Blakeslee, Sarah B, et al.
Publicado: (2023)

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials
por: George, Thomas J., et al.
Publicado: (2015)

Reinforcement Ring–Augmented Hip Arthroplasty: A 35-Year Follow-up
por: Ganz, Reinhold, et al.
Publicado: (2023)

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2018)

The 24-Hour Movement Paradigm: An integrated approach to the measurement and promotion of daily activity in cancer clinical trials
por: Shirazipour, Celina H., et al.
Publicado: (2023)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Continuous vs. discontinuous purification of isolated human islets: functional and morphological comparison
por: Buemi, Antoine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e9akjqnv373fn2aptfmqc2sps9